Vanda Pharmaceuticals Inc (NASDAQ:VNDA)

14.85
Delayed Data
As of Apr 20
 +0.10 / +0.68%
Today’s Change
11.90
Today|||52-Week Range
20.40
-2.30%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$904.2M

Company Description

Vanda Pharmaceuticals, Inc. is a global biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve the lives of patients. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Contact Information

Vanda Pharmaceuticals, Inc.
2200 Pennsylvania Avenue NW
Washington District Of Columbia 20037
P:(202) 734-3400
Investor Relations:
(202) 734-3428

Employees

Shareholders

Other institutional49.44%
Individual stakeholders34.29%
Mutual fund holders31.97%

Top Executives

Mihael Hristos PolymeropoulosPresident, Chief Executive Officer & Director
James Patrick KellyChief Financial Officer, Treasurer & Senior VP
Gian Piero ReverberiChief Commercial Officer & Senior Vice President
Richard L. GulinoSecretary, Senior VP & General Counsel
Gunther BirznieksSenior Vice President-Business Development